Regeneron Pharmaceuticals Gestion

Gestion contrôle des critères 4/4

Le PDG Regeneron Pharmaceuticals est Leonard Schleifer, nommé en Jan1988, a un mandat de 36.83 ans. La rémunération annuelle totale est $ 8.18M, composée du salaire de 22.9% et des bonus 77.1%, y compris les actions et options de la société. détient directement 2.23% des actions de la société, d'une valeur de $ 1.78B. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 7.2 ans et 17.9 ans.

Informations clés

Leonard Schleifer

Directeur général

US$8.2m

Rémunération totale

Pourcentage du salaire du PDG	22.9%
Durée du mandat du directeur général	36.8yrs
Propriété du PDG	2.2%
Durée moyenne d'occupation des postes de direction	7.2yrs
Durée moyenne du mandat des membres du conseil d'administration	17.9yrs

Mises à jour récentes de la gestion

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why

Jun 08

Recent updates

Regeneron: The Biotech Stock To Buy Now

Nov 19

Regeneron: Buying A Promising Pipeline At A Fair Price (Rating Upgrade)

Nov 04

Amgen Biosimilar And EYLEA Patent Dispute: What It Means For Regeneron Investors

Sep 25

Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?

Sep 09

Regeneron Stock: Valuation Now Demands More Growth

Aug 26

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 81% Above Its Share Price

Aug 22

Risks To Shareholder Returns Are Elevated At These Prices For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Aug 04

Regeneron's Robust Pipeline And Financial Health Signal Continued Growth

Aug 02

Regeneron: Downgrading My Outlook To 'Hold' Ahead Of Q2 Earnings

Jul 11

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why

Jun 08

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

May 21

Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks

May 06

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing

Apr 30

Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?

Apr 10

Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate

Mar 26

Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings

Feb 16

Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024

Feb 10

Analyse de la rémunération des PDG

Comment la rémunération de Leonard Schleifer a-t-elle évolué par rapport aux bénéfices de Regeneron Pharmaceuticals?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	US$5b
Jun 30 2024	n/a	n/a	US$4b
Mar 31 2024	n/a	n/a	US$4b
Dec 31 2023	US$8m	US$2m	US$4b
Sep 30 2023	n/a	n/a	US$4b
Jun 30 2023	n/a	n/a	US$4b
Mar 31 2023	n/a	n/a	US$4b
Dec 31 2022	US$7m	US$2m	US$4b
Sep 30 2022	n/a	n/a	US$5b
Jun 30 2022	n/a	n/a	US$6b
Mar 31 2022	n/a	n/a	US$8b
Dec 31 2021	US$6m	US$2m	US$8b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$6b
Mar 31 2021	n/a	n/a	US$4b
Dec 31 2020	US$135m	US$1m	US$4b
Sep 30 2020	n/a	n/a	US$3b
Jun 30 2020	n/a	n/a	US$3b
Mar 31 2020	n/a	n/a	US$2b
Dec 31 2019	US$21m	US$1m	US$2b
Sep 30 2019	n/a	n/a	US$2b
Jun 30 2019	n/a	n/a	US$2b
Mar 31 2019	n/a	n/a	US$2b
Dec 31 2018	US$27m	US$1m	US$2b
Sep 30 2018	n/a	n/a	US$2b
Jun 30 2018	n/a	n/a	US$2b
Mar 31 2018	n/a	n/a	US$1b
Dec 31 2017	US$27m	US$1m	US$1b

Rémunération vs marché: La rémunération totale de Leonard ($USD 8.18M ) est inférieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 12.73M ).

Rémunération et revenus: La rémunération de Leonard a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Leonard Schleifer (71 yo)

36.8yrs

Titularisation

US$8,184,338

Compensation

Dr. Leonard S. Schleifer, M.D., Ph D., Co-founded Regeneron Pharmaceuticals, Inc. in 1988 and has been its President and Chief Executive Officer since 1988 and is its Board Co-Chair since June 2023. He ser...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Leonard Schleifer	Co-Founder	36.8yrs	US$8.18m	2.23% $ 1.8b
George Yancopoulos	Co-Founder	23.8yrs	US$7.76m	1.07% $ 857.6m
Andrew Murphy	Executive Vice President of Research	5.8yrs	US$8.43m	0.048% $ 38.2m
Daniel Van Plew	Executive VP and GM of Industrial Operations & Product Supply	16.6yrs	US$8.76m	0.031% $ 25.2m
Christopher Fenimore	Senior VP of Finance & CFO	less than a year	pas de données	0.017% $ 13.9m
Patrice Gilooly	Senior Vice President of Quality Assurance & Operations	4.8yrs	pas de données	pas de données
Bob McCowan	Senior VP of IT & Chief Information Officer	3.8yrs	pas de données	pas de données
Ryan Crowe	Senior Vice President of Investor Relations & Strategic Analysis	no data	pas de données	pas de données
Joseph LaRosa	Executive VP	13.2yrs	US$7.13m	0.036% $ 28.5m
Melissa Lozner	Senior VP & Chief Compliance Officer	1.8yrs	pas de données	pas de données
Christina Chan	Senior Vice President of Corporate Affairs	no data	pas de données	pas de données
Sally Paull	Executive Vice President of Human Resources	8.6yrs	pas de données	pas de données

7.2yrs

Durée moyenne de l'emploi

64.5yo

Âge moyen

Gestion expérimentée: L'équipe dirigeante de REGN est chevronnée et expérimentée (7.2 années d'ancienneté moyenne).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Leonard Schleifer	Co-Founder	36.8yrs	US$8.18m	2.23% $ 1.8b
George Yancopoulos	Co-Founder	23.8yrs	US$7.76m	1.07% $ 857.6m
Christine Poon	Lead Independent Director	14yrs	US$748.01k	0.00073% $ 583.8k
Arthur Ryan	Independent Director	21.8yrs	US$724.99k	0.016% $ 13.1m
Michael Brown	Independent Director	33.4yrs	US$728.99k	0.012% $ 9.3m
Joseph Goldstein	Independent Director	33.4yrs	US$709.99k	0.0046% $ 3.7m
George Sing	Independent Director	36.8yrs	US$724.99k	0.026% $ 21.1m
N. Coles	Independent Director	7.8yrs	US$704.99k	0.000010% $ 8.0k
Craig Thompson	Independent Director	2.1yrs	US$247.79k	0% $ 0
Huda Zoghbi	Independent Director	8.2yrs	US$714.99k	0% $ 0
Bonnie Bassler	Independent Director	8.2yrs	US$709.99k	0.0013% $ 1.0m
Kathryn Guarini	Independent Director	1.2yrs	US$1.03m	0% $ 0

17.9yrs

Durée moyenne de l'emploi

71yo

Âge moyen

Conseil d'administration expérimenté: Le conseil d'administration de la REGN est chevronné et expérimenté ( 17.9 années d'ancienneté moyenne).

Regeneron Pharmaceuticals Gestion

Gestion contrôle des critères 4/4

Informations clés

Mises à jour récentes de la gestion

Senior VP of Finance & CFO recently sold US$6.4m worth of stock

Executive Vice President of Research exercised options and sold US$15m worth of stock

Insider recently sold US$5.6m worth of stock

Executive VP exercised options and sold US$5.6m worth of stock

Co-Founder exercised options and sold US$1.0m worth of stock

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why

Recent updates

Regeneron: The Biotech Stock To Buy Now

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Review the Resubmission of the Supplemental Biologics License Application for Dupixent®?

Regeneron Pharmaceuticals, Inc. to Present Hematology Pipeline Data At Ash 2024 Annual Meeting

Regeneron Pharmaceuticals, Inc. and Sanofi Receive European Union Approval For Dupixent In Young Children With Eosinophilic Esophagitis

Regeneron: Buying A Promising Pipeline At A Fair Price (Rating Upgrade)

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Regeneron Pharmaceuticals, Inc. Announces Positive Three-Year (156-Week) Data for EYLEA HD® (Aflibercept) Injection 8 mg from an Extension Study of the Phase 3 PHOTON Trial in Patients with Diabetic Macular Edem

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Regeneron Pharmaceuticals, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Amgen Biosimilar And EYLEA Patent Dispute: What It Means For Regeneron Investors

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Approves Dupixent (Dupilumab) as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps

Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?

Senior VP of Finance & CFO recently sold US$6.4m worth of stock

Regeneron Pharmaceuticals, Inc Announces Ordspono (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

Regeneron Stock: Valuation Now Demands More Growth

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 81% Above Its Share Price

Regeneron Provides Update on Biologics License Application for Linvoseltamab

Executive Vice President of Research exercised options and sold US$15m worth of stock

Insider recently sold US$5.6m worth of stock

Risks To Shareholder Returns Are Elevated At These Prices For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Regeneron's Robust Pipeline And Financial Health Signal Continued Growth

Regeneron: Downgrading My Outlook To 'Hold' Ahead Of Q2 Earnings

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in the European Union as the First-Ever Targeted Therapy for Patients with COPD

Regeneron Pharmaceuticals, Inc. Announces Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

Regeneron Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Regeneron Pharmaceuticals, Inc Announces Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine

Executive VP exercised options and sold US$5.6m worth of stock

Regeneron Pharmaceuticals, Inc. Announces 14-Month Median Follow-Up Data from the Pivotal Phase 1/2 Linker-MM1 Trial of Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma

Co-Founder exercised options and sold US$1.0m worth of stock

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why

Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. Announces Positive New Results from an Ongoing Phase 1/2 Trial Evaluating its First-in-Class Costimulatory Bispecific Antibody, REGN7075 (EGFRxCD28)

Regeneron Pharmaceuticals, Inc. and Sanofi Presents Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in the New England Journal of Medicine

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Co-Founder exercised options and sold US$104m worth of stock

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application (sBLA) for Dupixent

Regeneron Pharmaceuticals, Inc. Announces Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness Within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks

Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks

New minor risk - Shareholder dilution

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) announces an Equity Buyback for $3,000 million worth of its shares.

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing

Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?

Regeneron Pharmaceuticals, Inc. Announces Positive Pivotal Data from the Phase 1/2 LINKER-MM1 Trial of Linvoseltamab in Patients with Heavily Pre-Treated Multiple Myeloma

Regeneron Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2024

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) completed the acquiistion of R&D pipeline from 2seventy bio, Inc. (NasdaqGS:TSVT) for $20 million.

Regeneron Pharmaceuticals, Inc Provides Update on Biologics License Application for Odronextamab

Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate

Executive Vice President of Research exercised options and sold US$11m worth of stock

Regeneron Pharmaceuticals, Inc.'s Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol

Regeneron Pharmaceuticals, Inc. Announces the Lancet Published One-Year Results from the Pivotal Pulsar and Photon Trials for EYLEA HD (Aflibercept) Injection 8 Mg

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts Dupixent®? (Dupilumab) Sbla for Treatment of Copd with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. Announces Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review

Co-Founder exercised options and sold US$68m worth of stock

Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings

Regeneron Pharmaceuticals, Inc. and Sanofi Announces the Ministry of Health, Labor and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab) for the Treatment of Chronic Spontaneous Urticaria

Insider exercised options and sold US$14m worth of stock

Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024

Insider recently sold US$7.6m worth of stock

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen